4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases
This study evaluated the feasibilities and outcomes following four-dimensional magnetic resonance imaging (4D-MRI) assisted stereotactic body radiation therapy (SBRT) for unresectable colorectal liver metastases (CRLMs). From March 2018 to January 2022, we identified 76 unresectable CRLMs patients w...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Clinical and Translational Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405630823001398 |
| _version_ | 1827325505812037632 |
|---|---|
| author | Hongzhi Wang Xuan Zheng Jiawen Sun Xianggao Zhu Dezuo Dong Yi Du Zhongsu Feng Jian Gong Hao Wu Jianhao Geng Shuai Li Maxiaowei Song Yangzi Zhang Zhiyan Liu Yong Cai Yongheng Li Weihu Wang |
| author_facet | Hongzhi Wang Xuan Zheng Jiawen Sun Xianggao Zhu Dezuo Dong Yi Du Zhongsu Feng Jian Gong Hao Wu Jianhao Geng Shuai Li Maxiaowei Song Yangzi Zhang Zhiyan Liu Yong Cai Yongheng Li Weihu Wang |
| author_sort | Hongzhi Wang |
| collection | DOAJ |
| description | This study evaluated the feasibilities and outcomes following four-dimensional magnetic resonance imaging (4D-MRI) assisted stereotactic body radiation therapy (SBRT) for unresectable colorectal liver metastases (CRLMs). From March 2018 to January 2022, we identified 76 unresectable CRLMs patients with 123 lesions who received 4D-MRI guided SBRT in our institution. 4D-MRI simulation with or without abdominal compression was conducted for all patients. The prescription dose was 50–65 Gy in 5–12 fractions. The image quality of computed tomography (CT) and MRI were compared using the Clarity Score. Clinical outcomes and toxicity profiles were evaluated. 4D-MRI improved the image quality compared with CT images (mean Clarity Score: 1.67 vs 2.88, P < 0.001). The abdominal compression reduced motions in cranial–caudal direction (P = 0.03) with two phase T2 weighted images assessing tumor motion. The median follow-up time was 12.5 months. For 98 lesions assessed for best response, the complete response, partial response and stable disease rate were 57.1 %, 30.6 % and 12.2 %, respectively. The local control (LC) rate at 1 year was 97.3 %. 46.1 % of patients experienced grade 1–2 toxicities and only 2.6 % patients experienced grade 3 hematologic toxicities. The 4D-MRI technique allowed accurate target delineation and motion tracking in unresectable CRLMs patients. Favorable LC rate and mild toxicities were achieved. This study provided evidence for using 4D-MRI assisted SBRT as an alternative treatment in unresectable CRLMs. |
| first_indexed | 2024-03-07T14:29:14Z |
| format | Article |
| id | doaj.art-94e6a637c4c4411ab4c8f8ffc5675def |
| institution | Directory Open Access Journal |
| issn | 2405-6308 |
| language | English |
| last_indexed | 2024-03-07T14:29:14Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Clinical and Translational Radiation Oncology |
| spelling | doaj.art-94e6a637c4c4411ab4c8f8ffc5675def2024-03-06T05:27:42ZengElsevierClinical and Translational Radiation Oncology2405-63082024-03-01451007144D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastasesHongzhi Wang0Xuan Zheng1Jiawen Sun2Xianggao Zhu3Dezuo Dong4Yi Du5Zhongsu Feng6Jian Gong7Hao Wu8Jianhao Geng9Shuai Li10Maxiaowei Song11Yangzi Zhang12Zhiyan Liu13Yong Cai14Yongheng Li15Weihu Wang16Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaCorresponding Author: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, No. 52 Fu-cheng Road, Haidian District, Beijing 100142, China (Wei-Hu Wang).; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing 100142, ChinaThis study evaluated the feasibilities and outcomes following four-dimensional magnetic resonance imaging (4D-MRI) assisted stereotactic body radiation therapy (SBRT) for unresectable colorectal liver metastases (CRLMs). From March 2018 to January 2022, we identified 76 unresectable CRLMs patients with 123 lesions who received 4D-MRI guided SBRT in our institution. 4D-MRI simulation with or without abdominal compression was conducted for all patients. The prescription dose was 50–65 Gy in 5–12 fractions. The image quality of computed tomography (CT) and MRI were compared using the Clarity Score. Clinical outcomes and toxicity profiles were evaluated. 4D-MRI improved the image quality compared with CT images (mean Clarity Score: 1.67 vs 2.88, P < 0.001). The abdominal compression reduced motions in cranial–caudal direction (P = 0.03) with two phase T2 weighted images assessing tumor motion. The median follow-up time was 12.5 months. For 98 lesions assessed for best response, the complete response, partial response and stable disease rate were 57.1 %, 30.6 % and 12.2 %, respectively. The local control (LC) rate at 1 year was 97.3 %. 46.1 % of patients experienced grade 1–2 toxicities and only 2.6 % patients experienced grade 3 hematologic toxicities. The 4D-MRI technique allowed accurate target delineation and motion tracking in unresectable CRLMs patients. Favorable LC rate and mild toxicities were achieved. This study provided evidence for using 4D-MRI assisted SBRT as an alternative treatment in unresectable CRLMs.http://www.sciencedirect.com/science/article/pii/S2405630823001398Colorectal cancer liver metastases4D-MRIStereotactic body radiation therapyOutcomes |
| spellingShingle | Hongzhi Wang Xuan Zheng Jiawen Sun Xianggao Zhu Dezuo Dong Yi Du Zhongsu Feng Jian Gong Hao Wu Jianhao Geng Shuai Li Maxiaowei Song Yangzi Zhang Zhiyan Liu Yong Cai Yongheng Li Weihu Wang 4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases Clinical and Translational Radiation Oncology Colorectal cancer liver metastases 4D-MRI Stereotactic body radiation therapy Outcomes |
| title | 4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases |
| title_full | 4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases |
| title_fullStr | 4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases |
| title_full_unstemmed | 4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases |
| title_short | 4D-MRI assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases |
| title_sort | 4d mri assisted stereotactic body radiation therapy for unresectable colorectal cancer liver metastases |
| topic | Colorectal cancer liver metastases 4D-MRI Stereotactic body radiation therapy Outcomes |
| url | http://www.sciencedirect.com/science/article/pii/S2405630823001398 |
| work_keys_str_mv | AT hongzhiwang 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT xuanzheng 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT jiawensun 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT xianggaozhu 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT dezuodong 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT yidu 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT zhongsufeng 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT jiangong 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT haowu 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT jianhaogeng 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT shuaili 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT maxiaoweisong 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT yangzizhang 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT zhiyanliu 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT yongcai 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT yonghengli 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases AT weihuwang 4dmriassistedstereotacticbodyradiationtherapyforunresectablecolorectalcancerlivermetastases |